Study highlights potential of ASO therapy to treat Fuchs endothelial corneal dystrophy patients

A proof-of-concept study carried out at UCL Institute of Ophthalmology with funding from Fight for Sight has highlighted the potential of a targeted antisense oligonucleotide therapy to treat Fuchs endothelial corneal dystrophy patients with a mutation in the TCF4 gene.

Full Story →